Kjersti Flatmark
Oslo University Hospital
Publications 149
#1Hanna Abrahamsson (Ahus: Akershus University Hospital)
#2Alina Carmen Porojnicu (Ahus: Akershus University Hospital)H-Index: 23
Last.Anne Hansen Ree (Ahus: Akershus University Hospital)H-Index: 24
view all 11 authors...
Background Following curative-intent neoadjuvant therapy in locally advanced rectal cancer, metastatic progression is still dominant. We investigated if patients’ circulating 25-hydroxyvitamin D [25(OH)D] levels were associated with outcome.
#1Bastian Fromm (Oslo University Hospital)H-Index: 11
#2Diana Domanska (University of Oslo)H-Index: 3
Last.Kevin J. Peterson (Dartmouth College)H-Index: 47
view all 0 authors...
#1Olaf Sørensen (Oslo University Hospital)H-Index: 3
#2Anders Andersen (Oslo University Hospital)H-Index: 11
Last.Kjersti Flatmark (Oslo University Hospital)H-Index: 26
view all 5 authors...
Pseudomyxoma peritonei (PMP) is a rare cancer commonly originating from appendiceal neoplasms that presents with mucinous tumor spread in the peritoneal cavity. Patients with PMP are treated with curative intent by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The value of adding HIPEC to CRS has not been proven in randomized trials, and the objective of this study was to investigate the efficacy of intraperitoneal mitomycin C (MMC) and regional hyperthermia ...
#1Sebastian Meltzer (Ahus: Akershus University Hospital)H-Index: 3
#2Tonje Bjørnetrø (University of Oslo)H-Index: 1
Last.Kathrine Røe Redalen (NTNU: Norwegian University of Science and Technology)H-Index: 6
view all 10 authors...
Abstract As many as 30% to 40% of locally advanced rectal cancer (LARC) patients experience metastatic progression of the disease. Recognizing the potential of the genetic cargo in tumor-derived exosomes, we hypothesized that plasma exosomal microRNA (miRNA) may reflect biological aggressiveness in LARC and provide new markers for rectal cancer aggressiveness and risk stratification. In a prospective LARC cohort ( NCT01816607 ), plasma samples were collected from 29 patients at the time of diagn...
#1Vigdis Nygaard (Oslo University Hospital)H-Index: 9
#2V.J. Dagenborg (Oslo University Hospital)
Last.Kjersti Flatmark (Oslo University Hospital)H-Index: 26
view all 12 authors...
Colorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer death in the Western world. Up to 50% of CRC patients develop metastatic disease and the liver is the most common site. The recently identified consensus molecular subtypes (CMS1-4) based on analyses of primary CRC have prognostic and therapeutic implications, but it is unclear whether these molecular subtypes are valid for metastatic disease. The tumor microenvironment plays a major role in the dynamic shapi...
#1Vivi Ann FlørenesH-Index: 37
Last.Gunhild Maelandsmo (Oslo University Hospital)H-Index: 1
view all 17 authors...
Abstract Although clinical management of melanoma has changed considerably in recent years, intrinsic treatment resistance remains a severe problem and strategies to design personal treatment regimens are highly warranted. We have applied a three-dimensional (3D) ex vivo drug efficacy assay, exposing disaggregated cells from 38 freshly harvested melanoma lymph node metastases and 21 patient derived xenografts (PDXs) to clinical relevant drugs for 7 days, and examined its potential to evaluate th...
#1Anne Hansen Ree (University of Oslo)H-Index: 24
#2Vigdis Nygaard (Oslo University Hospital)H-Index: 9
Last.Gunhild Mari Mælandsmo (University of Tromsø)H-Index: 43
view all 13 authors...
Most patients whose large bowel cancer has spread to other organs do not respond to immune therapy. We detected a rare gene mutation, termed 9p24.1 copy-number gain (CNG), in an otherwise incurable colorectal cancer that provoked an immune therapy response. We identified this gene mutation by gene-panel sequencing of DNA from a liver metastasis biopsy from a patient who had disease refractory to standard therapies. Following immune checkpoint blockade (ICB) with pembrolizumab (anti–PD-1), the pa...